Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 14,800 shares, a decline of 52.3% from the August 31st total of 31,000 shares. Based on an average daily volume of 144,500 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the company’s stock are sold short.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Xilio Therapeutics stock. XTX Topco Ltd purchased a new position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,289 shares of the company’s stock, valued at approximately $32,000. XTX Topco Ltd owned approximately 0.08% of Xilio Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 54.29% of the company’s stock.
Xilio Therapeutics Trading Up 2.6 %
Shares of NASDAQ XLO opened at $0.75 on Thursday. The company has a fifty day moving average price of $0.86 and a 200 day moving average price of $0.97. The firm has a market cap of $27.76 million, a PE ratio of -0.29 and a beta of -0.10. Xilio Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.89.
About Xilio Therapeutics
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.
Featured Articles
- Five stocks we like better than Xilio Therapeutics
- How to Capture the Benefits of Dividend Increases
- Should You Invest in Treasury Bills?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- 5 Top Rated Dividend Stocks to Consider
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.